GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » EV-to-Revenue

Biotechnology Assets (XMAD:BST) EV-to-Revenue : 7.40 (As of May. 11, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biotechnology Assets's enterprise value is €26.66 Mil. Biotechnology Assets's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €3.60 Mil. Therefore, Biotechnology Assets's EV-to-Revenue for today is 7.40.

The historical rank and industry rank for Biotechnology Assets's EV-to-Revenue or its related term are showing as below:

XMAD:BST' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.95   Med: 9   Max: 59.2
Current: 7.4

During the past 13 years, the highest EV-to-Revenue of Biotechnology Assets was 59.20. The lowest was 1.95. And the median was 9.00.

XMAD:BST's EV-to-Revenue is ranked better than
52.45% of 1039 companies
in the Biotechnology industry
Industry Median: 8.37 vs XMAD:BST: 7.40

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-11), Biotechnology Assets's stock price is €0.3445. Biotechnology Assets's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.06. Therefore, Biotechnology Assets's PS Ratio for today is 5.47.


Biotechnology Assets EV-to-Revenue Historical Data

The historical data trend for Biotechnology Assets's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets EV-to-Revenue Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.49 9.61 7.35 8.91 8.19

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.35 - 8.91 - 8.19

Competitive Comparison of Biotechnology Assets's EV-to-Revenue

For the Biotechnology subindustry, Biotechnology Assets's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotechnology Assets's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's EV-to-Revenue falls into.



Biotechnology Assets EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biotechnology Assets's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=26.656/3.602
=7.40

Biotechnology Assets's current Enterprise Value is €26.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €3.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotechnology Assets  (XMAD:BST) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biotechnology Assets's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.3445/0.063
=5.47

Biotechnology Assets's share price for today is €0.3445.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotechnology Assets EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotechnology Assets (XMAD:BST) Business Description

Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.